Novartis agreed to acquire Pikavation Therapeutics from parent Synnovation Therapeutics for $2B upfront plus up to $1B in milestones. The lead asset SNV4818 is an oral pan-mutant-selective PI3Kalpha inhibitor in Phase 1/2 for breast cancer (~40% of HR+/HER2- patients harbor PIK3CA mutations). Transaction is expected to close in H1 2026.
Key facts
AnnouncedMar 20, 2026
Deal value$3.0B
Deal typeAcquisition/Merger
Therapeutic areaHR+/HER2- breast cancer and other advanced solid tumors
IndicationsHR+/HER2- breast cancer and other advanced solid tumors